|
KMID : 1225720220140060604
|
|
Allergy, Asthma & Immunology Research : AAIR
2022 Volume.14 No. 6 p.604 ~ p.652
|
|
|
Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update
|
|
Wang Chengshuo
Bao Yixiao
Chen Jianjun
Chen Xiaoyang
Cheng Lei
Guo Yin Shi
Hao Chuangli
Lai He
Li Huabin
Liu Yun
Liu Zheng
Lou Hongfei
Lv Wei
Nong Guangmin
Qiu Qianhui
Ren Xiumin
Shao Jie
Shen Yi-Hong
Shi Li
Song Xi cheng
Song Yuxin
Tang Suping
Wang Hongtian
Wang Xiangdong
Wang Xueyan
Wang Zhenlin
Wei Qingyu
Xie Hua
Xing Zhimin
Xu Rui
Xu Yu
Yang Qintai
Yao Hongmei
Ye Jing
You Yiwen
Yu Hongmeng
Yu Yongmei
Zhang Huanping
Zhang Gehua
Zhang Yuan
Zhi Yuxiang
Zhou Weikang
Zhu Xinhua
Chai Ruonan
Chen Dehua
Guan Kai
Huang Zizhen
Huang Yanran
Ma Tingting
Ma Yuemei
Yifan Meng
Ren Lei
Wang Jianxing
Wang Nan
Xian Mo
Xiang Rong
Zheng Ming
Zhang Luo
|
|
|
Abstract
|
|
|
|
In the last few decades, there has been a progressive increase in the prevalence of allergic rhinitis (AR) in China, where it now affects approximately 250 million people. AR prevention and treatment include allergen avoidance, pharmacotherapy, allergen immunotherapy (AIT), and patient education, among which AIT is the only curative intervention. AIT targets the disease etiology and may potentially modify the immune system as well as induce allergen-specific immune tolerance in patients with AR. In 2017, a team of experts from the Chinese Society of Allergy (CSA) and the Chinese Allergic Rhinitis Collaborative Research Group (C2AR2G) produced the first English version of Chinese AIT guidelines for AR. Since then, there has been considerable progress in basic research of and clinical practice for AIT, especially regarding the role of follicular regulatory T (TFR) cells in the pathogenesis of AR and the use of allergen-specific immunoglobulin E (sIgE) in nasal secretions for the diagnosis of AR. Additionally, potential biomarkers, including TFR cells, sIgG4, and sIgE, have been used to monitor the incidence and progression of AR. Moreover, there has been a novel understanding of AIT during the coronavirus disease 2019 pandemic. Hence, there was an urgent need to update the AIT guideline for AR by a team of experts from CSA and C2AR2G. This document aims to serve as professional reference material on AIT for AR treatment in China, thus improving the development of AIT across the world.
|
|
|
KEYWORD
|
|
|
Allergen immunotherapy, allergic rhinitis, guidelines, China, immunoglobulin E, biomarkers, rush immunotherapy, house dust mites, subcutaneous immunotherapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|
|